학술논문
Efficacy and safety results after >3.5 years of treatment with the Bruton’s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study
Document Type
Article
Author
Source
In: Multiple Sclerosis Journal . (Multiple Sclerosis Journal, April 2024, 30(4-5):558-570)
Subject
Language
English
ISSN
14770970
13524585
13524585